Literature DB >> 20506332

Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis.

David C Wilson1, Anthony D Marinov, Harry C Blair, Daniel S Bushnell, Susan D Thompson, Yury Chaly, Raphael Hirsch.   

Abstract

OBJECTIVE: To examine both the source of follistatin-like protein 1 (FSTL-1) and the factors that induce its expression in arthritis, and to determine whether juvenile rheumatoid arthritis (JRA) is characterized by overexpression of FSTL-1.
METHODS: FSTL-1 expression patterns were analyzed by immunohistochemical staining of joint tissue derived from mice with collagen-induced arthritis. Induction of FSTL-1 secretion was assessed in osteoblasts, adipocytes, and human fibroblast-like synoviocytes in response to transforming growth factor beta (TGFbeta), interleukin-1beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), and IL-6. In addition, sera and synovial fluid from children with oligoarticular, polyarticular, or systemic-onset JRA were assayed for FSTL-1 using a custom enzyme-linked immunosorbent assay. FSTL-1 concentrations in these patients were assessed for correlations with the erythrocyte sedimentation rate (ESR) and platelet count.
RESULTS: Immunohistochemical staining of murine joint sections demonstrated expression of FSTL-1 in all cell types of the mesenchymal lineage, including osteocytes, chondrocytes, adipocytes, and fibroblasts. FSTL-1 could be induced in osteoblasts, adipocytes, and human fibroblast-like synoviocytes by TGFbeta, IL-1beta, TNFalpha, and IL-6. The IL-1beta response was significantly greater than the TNFalpha response (P < 0.05). In human serum and synovial fluid, only those samples from children with the systemic-onset JRA subtype had elevated concentrations of FSTL-1. The synovial fluid concentrations of FSTL-1 were 2-3-fold higher than the serum concentrations. The elevation in serum FSTL-1 concentrations seen in children with systemic-onset JRA correlated closely with elevations in the ESR and platelet count.
CONCLUSION: These findings demonstrate that the arthritic joint matrix is a major source of FSTL-1 and that IL-1beta is a central mediator of FSTL-1 secretion. Furthermore, FSTL-1 may represent a useful biomarker of disease activity in systemic-onset JRA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20506332      PMCID: PMC2921021          DOI: 10.1002/art.27485

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

Authors:  Philip N Hawkins; Helen J Lachmann; Michael F McDermott
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

2.  Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease.

Authors:  Philip N Hawkins; Alison Bybee; Ebun Aganna; Michael F McDermott
Journal:  Arthritis Rheum       Date:  2004-08

3.  Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

Authors:  Pierre Quartier; Pierre Taupin; Franck Bourdeaut; Irène Lemelle; Pascal Pillet; Michel Bost; Jean Sibilia; Isabelle Koné-Paut; Sylvie Gandon-Laloum; Marc LeBideau; Brigitte Bader-Meunier; Richard Mouy; Marianne Debré; Paul Landais; Anne-Marie Prieur
Journal:  Arthritis Rheum       Date:  2003-04

4.  A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis.

Authors:  J T Cassidy; J E Levinson; J C Bass; J Baum; E J Brewer; C W Fink; V Hanson; J C Jacobs; A T Masi; J G Schaller
Journal:  Arthritis Rheum       Date:  1986-02

5.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

6.  Anti-keratin antibodies in rheumatoid arthritis.

Authors:  B J Young; R K Mallya; R D Leslie; C J Clark; T J Hamblin
Journal:  Br Med J       Date:  1979-07-14

7.  Follistatin-like protein 1 promotes arthritis by up-regulating IFN-gamma.

Authors:  Suzanne D Clutter; David C Wilson; Anthony D Marinov; Raphael Hirsch
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

8.  Ameliorative effects of follistatin-related protein/TSC-36/FSTL1 on joint inflammation in a mouse model of arthritis.

Authors:  Daisuke Kawabata; Masao Tanaka; Takao Fujii; Hisanori Umehara; Yoshimasa Fujita; Hajime Yoshifuji; Tsuneyo Mimori; Shoichi Ozaki
Journal:  Arthritis Rheum       Date:  2004-02

9.  Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.

Authors:  Daniel J Lovell; Edward H Giannini; Andreas Reiff; Olcay Y Jones; Rayfel Schneider; Judyann C Olson; Leonard D Stein; Abraham Gedalia; Norman T Ilowite; Carol A Wallace; Mary Lange; Barbara K Finck; Daniel J Burge
Journal:  Arthritis Rheum       Date:  2003-01

10.  Potential preventive effects of follistatin-related protein/TSC-36 on joint destruction and antagonistic modulation of its autoantibodies in rheumatoid arthritis.

Authors:  Masao Tanaka; Shoichi Ozaki; Daisuke Kawabata; Masaaki Kishimura; Fumio Osakada; Mitsuo Okubo; Masao Murakami; Kazuwa Nakao; Tsuneyo Mimori
Journal:  Int Immunol       Date:  2003-01       Impact factor: 4.823

View more
  36 in total

1.  FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine/chemokine expression.

Authors:  Yury Chaly; Anthony D Marinov; Leif Oxburgh; Daniel S Bushnell; Raphael Hirsch
Journal:  Arthritis Rheum       Date:  2011-10-17

2.  Plasma follistatin-like protein 1 is elevated in Kawasaki disease and may predict coronary artery aneurysm formation.

Authors:  Mark Gorelik; David C Wilson; Yona K Cloonan; Stanford T Shulman; Raphael Hirsch
Journal:  J Pediatr       Date:  2012-02-07       Impact factor: 4.406

3.  Follistatin-like protein 1 is a critical mediator of experimental Lyme arthritis and the humoral response to Borrelia burgdorferi infection.

Authors:  Brian T Campfield; Christi L Nolder; Anthony Marinov; Daniel Bushnell; Amy Davis; Caressa Spychala; Raphael Hirsch; Andrew J Nowalk
Journal:  Microb Pathog       Date:  2014-04-24       Impact factor: 3.738

4.  Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload.

Authors:  Masayuki Shimano; Noriyuki Ouchi; Kazuto Nakamura; Bram van Wijk; Koji Ohashi; Yasuhide Asaumi; Akiko Higuchi; David R Pimentel; Flora Sam; Toyoaki Murohara; Maurice J B van den Hoff; Kenneth Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

Review 5.  Diverse biological functions of the SPARC family of proteins.

Authors:  Amy D Bradshaw
Journal:  Int J Biochem Cell Biol       Date:  2012-01-09       Impact factor: 5.085

6.  Regulation of Pulmonary Bacterial Immunity by Follistatin-Like Protein 1.

Authors:  Matthew Henkel; Justin A Dutta; Jessica Partyka; Taylor Eddens; Raphael Hirsch; Jay K Kolls; Brian T Campfield
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

Review 7.  Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Authors:  Elizabeth D Mellins; Claudia Macaubas; Alexei A Grom
Journal:  Nat Rev Rheumatol       Date:  2011-06-07       Impact factor: 20.543

8.  Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications.

Authors:  Xuefeng B Ling; Jane L Park; Tanya Carroll; Khoa D Nguyen; Kenneth Lau; Claudia Macaubas; Edward Chen; Tzielan Lee; Christy Sandborg; Diana Milojevic; John T Kanegaye; Susanna Gao; Jane Burns; James Schilling; Elizabeth D Mellins
Journal:  Proteomics       Date:  2010-11-23       Impact factor: 3.984

9.  Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  Mark Gorelik; Ndate Fall; Mekibib Altaye; Michael G Barnes; Susan D Thompson; Alexei A Grom; Raphael Hirsch
Journal:  J Rheumatol       Date:  2013-05-15       Impact factor: 4.666

10.  Follistatin-like protein 1 enhances NLRP3 inflammasome-mediated IL-1β secretion from monocytes and macrophages.

Authors:  Yury Chaly; Yu Fu; Anthony Marinov; Bruce Hostager; Wei Yan; Brian Campfield; John A Kellum; Daniel Bushnell; Yudong Wang; Jerry Vockley; Raphael Hirsch
Journal:  Eur J Immunol       Date:  2014-02-20       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.